Cargando…
The Emergent Landscape of Detecting EGFR Mutations Using Circulating Tumor DNA in Lung Cancer
The advances in targeted therapies for lung cancer are based on the evaluation of specific gene mutations especially the epidermal growth factor receptor (EGFR). The assays largely depend on the acquisition of tumor tissue via biopsy before the initiation of therapy or after the onset of acquired re...
Autores principales: | Huang, Wei-Lun, Wei, Fang, Wong, David T., Lin, Chien-Chung, Su, Wu-Chou |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4584057/ https://www.ncbi.nlm.nih.gov/pubmed/26448936 http://dx.doi.org/10.1155/2015/340732 |
Ejemplares similares
-
Five Technologies for Detecting the EGFR T790M Mutation in the Circulating Cell-Free DNA of Patients With Non-small Cell Lung Cancer: A Comparison
por: Chen, Yi-Lin, et al.
Publicado: (2019) -
Ultra-Short Circulating Tumor DNA (usctDNA) in Plasma and Saliva of Non-Small Cell Lung Cancer (NSCLC) Patients
por: Li, Feng, et al.
Publicado: (2020) -
Comparative Analysis of Two Methods for the Detection of EGFR Mutations in Plasma Circulating Tumor DNA from Lung Adenocarcinoma Patients
por: Hung, Ming-Szu, et al.
Publicado: (2019) -
Correlation of circulating tumor DNA EGFR mutation levels with clinical outcomes in patients with advanced lung adenocarcinoma
por: Liu, Xiang-Liang, et al.
Publicado: (2021) -
EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6
por: Wu, Yi-Long, et al.
Publicado: (2017)